Source disclosure: January 30, 2026
KISSEI PHARMACEUTICAL CO.,LTD. [4547.T]
TOKYO, Jan 30 (Pulse News Wire) -- Kissei Pharmaceutical Co., Ltd. (4547.T), led by Chairman Shinawa Rikuuo, announced on January 30 that it will implement special dividends as part of its celebration marking the company's 80th anniversary. The decision was made during a board meeting held on the same day.
The company, which was established on August 9, 2026, is set to celebrate its 80th year since its founding. In line with its mid-term business plan Beyond 80, launched in April 2025, Kissei aims to achieve sustainable growth based on the legacy built by its predecessors. To express gratitude towards shareholders who have supported the company throughout these years, Kissei plans to distribute two rounds of commemorative dividends in fiscal year 2026 and the first half of fiscal year 2027.
For the fiscal year ending March 2026, Kissei will add a one-time dividend of 40 yen per share to the regular dividend of 60 yen, bringing the total dividend per share to 100 yen. This additional dividend is expected to amount to approximately 4.145 billion yen in total. The official approval for this dividend is scheduled to be finalized at the board meeting in May and confirmed at the annual general meeting planned for late June.
Furthermore, Kissei has also decided to issue an additional 40 yen per shareas a commemorative dividend for the interim period of the fiscal year ending March 2027. Details regarding the ordinary dividends for both the interim and final periods of fiscal year 2027 will be disclosed in May when the company releases its earnings report for the fiscal year ending March 2026.
Kissei’s basic policy on profit distribution emphasizes balancing investment in growth opportunities with stable dividend payouts. The company targets a payout ratio of over 40% through progressive dividends. It adheres to a bi-annual dividend schedule, with decisions on interim dividends made by the board and final dividends approved by shareholders. Additionally, Kissei reserves the right under its articles of incorporation to declare interim dividends based on a resolution by the board every September 30th.
Regarding retained earnings, the company intends to allocate funds toward research and development of pharmaceuticals demanded by patients, aligning with anticipated regulatory changes and global trends. Such investments are expected to contribute to future profitability and fair returns to shareholders.
These measures reflect Kissei Pharmaceutical's commitment to honoring its past while investing in its future, ensuring continued value creation for all stakeholders.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing